Herpes virus is a naturally neurotropic virus that in natural infections shows a predilection for neurons of the peripheral nervous system. A unique aspect of the biology of HSV is its ability to establish a life-long latent state in neurons, latent genomes have no detectable effect on nerve cell function. Taking advantage of neural tropism and natural latency, we have developed a series of vectors designed to deliver and express genes in neurons for a variety of potential therapeutic applications. 1 The therapeutic gene product may be designed to function within the cell in which it is expressed, may be released from that cell to function locally either in an autocrine or paracrine fashion, or it may be released into the circulation to function systemically. This review will focus on recent studies showing that HSV-based vectors may be useful in the treatment of diseases characterized by neurodegeneration.
Biology of HSV
HSV is an enveloped double-stranded DNA virus with more than 80 identified genes encoded for by the 152 kb viral genome. 2 The virus envelope contains at least 10 glycoproteins which function in the attachment and penetration of the virus. Initial binding of the virus to cell surface glycosaminoglycans (GAGs), primarily heparan and dermatan sulfate is mediated by glycoproteins C (gC) and B (gB). 3, 4 This initial binding is followed by specific interactions between gD and identified receptors (HveM herpes virus entry mediators) HveA and HveC. HveA is a member of the TNF p75 receptor superfamily, but is generally thought not to be expressed in the nervous system. HveC belongs to the immunoglobulin superfamily and is highly expressed in the nervous system. 6 Sequential attachment to GAGs followed by specific interactions with HVEMs leads to fusion of the virus envelope with the cell surface membrane and entry of the viral capsid with its surrounding tegument proteins into the cell. The mechanism through which viral penetration into the cell occurs is not well understood, but requires multiple glycoproteins (gB, gH/gL and gD).
Following entry into a neuron the capsid is carried by retrograde axonal transport along the cytoskeleton to the nucleus, where the DNA is injected through nuclear pores to initiate the cascade of lytic gene expression. Wild-type viral genes are expressed in a temporally regulated cascade. Immediate early (IE) genes are expressed after viral entry into the nucleus and in the absence of de novo viral protein synthesis. IE proteins activate expression of the early (E) genes, and following E genemediated synthesis of viral DNA, the IE proteins promote the expression of late (L) viral genes. The IE gene products are largely regulatory proteins, the E gene products are involved in viral DNA synthesis, and the L gene products are largely structural proteins of the virion. The expression of IE genes is enhanced by VP16, a structural protein that acts in concert with several cellular transcription factors including Oct-1 to activate transcription of the IE gene promoters through recognition of one or more copies of the consensus element TAATGARAT. One IE gene product, ICP4, is absolutely essential for viral replication. 7, 8 Mutants deleted for ICP4 were the first essential gene knockout HSV mutants to be constructed. 9 An important consequence of deleting ICP4 from HSV is that the temporal cascade of viral gene expression is incapable of proceeding past the IE phase of transcription except in cell lines designed to provide ICP4 in trans. Thus, despite the complexity of the virus genome, the great majority of virus gene expression can be eliminated by a single deletion mutation.
Multiply-deleted genomic HSV vectors
Although deletion of ICP4 is sufficient to create a vector that is incapable of replicating, the remaining IE gene products (ICP0, ICP22, ICP27 and ICP47) are abundantly expressed. The majority of these gene products can profoundly alter cell metabolism and gene expression and may be toxic to cells. Vector toxicity has been resolved by engineering virus mutants deleted for all the IE genes. 10, 11 A recombinant (d106) engineered to express only the IE protein ICP0 induces expression of a subset of cellular genes, while an isogenic recombinant (d109) which does not express any viral proteins had no appreciable effect on cellular gene expression. 11, 12 Thus the vectors deleted for multiple IE genes behave in a manner similar to UV-irradiated viral particles which are apathogenic to cells. These highly deleted vectors have several advantages. First, they can be propagated to high titers without the emergence of wild-type recombinants. Because the recombinant vector is propagated directly in complementing cells there is no helper virus. Second, the complete IE gene knockout vectors do not alter cell metabolism making them ideal for gene transfer to nonneuronal cells. Third, the expression of the LATs in neurons does not depend on expression of the IE genes making it possible to construct a highly defective vector that can readily persist in a latent-like state in neurons and transgenes can be expressed using the latency promoter.
In wild-type infection the virus either replicates, or alternatively enters a latent state, in which the genomes exist as circular or concatemermized intranuclear episomes in which the lytic functions are transcriptionally silent. It has been known for some time that viruses prevented from replicating are forced into the equivalent of latency. 13 Similarly, recombinant vectors deleted for one or more essential IE genes can establish a persistent state in which the lytic genes are essentially silent and the state of the genome may be similar to that of natural latency. In this state a single region of the latent genome continues to be transcribed producing a family of non-polyadenylated latency associated transcripts (LATs), which persist as intranuclear RNAs known to be stable intron lariates. 14, 15 Although the function of LATs is not known, their production (which may persist for the life of the host) serves as the hallmark of latent genomes in the nervous system and demonstrates that sequences may be transcribed from the latent genomes. It should be noted that only a fraction of latently infected cells express LATs at a level detectable by in situ hybridization (ISH), so that the demonstration of LATs by ISH under-represents the total number of latently infected neurons. 16, 17 
HSV-mediated expression of NGF
In recent studies we have found that HSV-based vectors deleted for multiple IE genes can be used to deliver neuroprotective macromolecules to neurons. Two different paradigms have been employed. Nerve growth factor (NGF) is the prototypical neurotrophic factor, originally identified by its ability to protect peripheral sensory and sympathetic neurons from programmed cell death during development. In addition to its action during development, NGF is able to protect adult sensory and sympathetic neurons against a variety of insults that include: axotomy, ionophore treatment, exposure to hydrogen peroxide, or excitatory amino acids. In animal models, systemic administration of high doses of NGF prevents the onset of peripheral neuropathy after toxin exposure or after the induction of diabetes by streptozotocin. The bioactivity of the 118 amino acid ␤ subunit can be assayed in vitro by its effect in inducing neuronal differentiation and neuritic sprouting in PC-12 cells.
Genomic HSV-based vectors containing the coding sequence for ␤-NGF under the transcriptional control of either the transiently active human cytomegalovirus immediate-early promoter (HCMV IEp) element, or a HSV latency active promoter (LAP2), produced biologically active NGF as measured by the differentiation and neuritic sprouting of transfected PC-12 cells. 18 NGF expression in trigeminal ganglia in vivo, following topical corneal infection and subsequent retrograde axonal transport, was high 3 days after inoculation with the HCMV IEp:NGF vector but fell by 21 days. 18 In contrast, the LAP2:NGF vector showed a low level of expression at 3 days but a high level at 21 days, consistent with the known kinetics of that promoter element. Vectormediated expression of NGF in neurons of the dorsal root ganglion in vitro was consistent with expression in trigeminal neurons in vivo with the HCMV IE promoter displaying transient activity whereas LAP2 remained active at 2 weeks (Figure 1 ). Vector-mediated NGF synthesis induced expression of superoxide dismutase and catalase, and was effective in protecting these cells from apoptosis induced by exposure to hydrogen peroxide ( Figure 1) . 18 This effect also demonstrated kinetics consistent with the known promoter activity, higher early with the HCMV IE promoter and at later times with the LAP2 element (Figure 1) . NGF activity is mediated by cell surface receptors (trkA and p75) which once activated by NGF binding to the extracellular domain of the receptor initiates a cascade of intracellular signals beginning with dimerization and autophosphorylation of the intracellular domain of the trkA, leading to phosphorylation of PLC, PI-3␤, and the adaptor protein Shc, and ultimately activation of a MAP kinase cascade. Because these actions are initiated by binding of NGF to the extracellular domain of the receptor, we presume that transgene-coded NGF must be released from transfected cells to bind to receptors on those and neighboring cells to produce the biological effect. This mode of action allows amplification of the biological effect achieved by release of trophic factors from the transduced cells.
The endocrine effect of transgene-produced NGF has been demonstrated systemically in rabbits and monkeys. Animals were inoculated into one knee joint with replication-defective HSV vectors containing the coding sequence for ␤-NGF under the control of either the LAP2 or HCMV:IEp promoter. Both vectors expressed NGF that could be detected in the joint space and in the plasma within weeks of vectors administration. 19 Expression persisted for more than 1 year. While the level of NGF in blood could be accounted for by the amount of injected virus, it appeared more likely that an autocrine loop driven by vector expression was responsible for the high levels observed. The NGF released into
Figure 1 HSV vector-mediated NGF expression protects DRG neurons from toxic insult. DRG neuronal cultures infected with the HCMV:NGF vector express high levels of NGF at 3 days that protects DRG neurons from apoptotic insult by increasing the levels of antioxidant enzymes such as SOD. In contrast, LAP2 driven NGF expression at 14 days blocks apoptotic insult and results in increased SOD enzyme activity. (Modified with permission from J Virol 73: 519-532.)
the joint space was sufficient to induce differentiation of NGF responsive PC12E2 cells (Figure 2 ).
HSV-mediated expression of bcl-2
Expression of trophic factors represents one potential approach to protecting neurons from a variety of insults or degenerative conditions. Alternatively, for those conditions in which neuronal cell death proceeds through apoptotic pathways, HSV-based vectors can be used to interrupt the apoptotic pathway at downstream sites through transgene-driven expression of anti-apoptotic peptides such as bcl-2. Bcl-2, a structural and functional homologue of the nematode protein CED-9 prevents the opening of the permeability transition complex of mitochondria and the subsequent release of cytochrome C among other functions. Bcl-2 is located on the cytoplasmic face of the mitochondrial outer membrane, the endoplasmic reticulum, and the nuclear envelope, and acts within the cell in which it is produced. We have studied a bcl-2 expressing vector in two model systems.
The neurotoxin 6-hydroxydopamine (6-OHDA) is widely used to model degeneration of dopaminergic neurons of the substantia nigra characteristic of Parkinson's disease. Injection of the toxin into striatum causes a subacute lesion with a well-defined morphologic, behavioral, and biochemical phenotype. p53 and Bax protein expression are up-regulated by exposure of cells to 6-Gene Therapy OHDA, and PC-12 cells exposed to 6-OHDA demonstrate cell shrinkage, chromatin condensation, membrane blebbing and DNA fragmentation characteristic of apoptosis. Dopamine-induced apoptosis of PC-12 cells is inhibited by overexpression of bcl-2, and cultured neurons from bcl-2 overexpressing transgenic mice are resistant to 6-OHDA toxicity in vitro. We therefore tested whether transgene-driven expression of bcl-2 could prevent degeneration of substantia nigra neurons characteristic of Parkinson's.
The human bcl-2 cDNA under the transcriptional control of the simian cytomegalovirus (SCMV) IEp was placed in the thymidine kinase (tk) locus of a genomic HSV vector deleted for the HSV IE genes ICP4, ICP22 and ICP27. 20 This vector produced immunoreactive bcl-2 in cultured cells, and protected cortical neurons in vitro from naturally occurring programmed cell death. The bcl-2 expression vector (or the control lacZ expressing vector) was injected directly into the substantia nigra unilaterally; at the same time fluorogold was injected into the striatum bilaterally in order to label neuronal cell bodies in the substantia nigra that project to the striatum. One week later 6-OHDA was injected unilaterally into striatum, using the same coordinates as for fluorogold. Two weeks after 6-OHDA injection the animals were killed and the survival of FG-labeled nigral neurons and tyrosine hydroxylase (TH) immunoreactivity of the lesioned substantia nigra compared between bcl-2 vectorinjected and control vector injected animals. 20 Bcl-2 produced from the vector prevented 6-OHDA induced degeneration of retrogradely labeled FG-positive neurons, and also preserved the TH immunoreactive phenotype of the lesioned neurons (Figure 3 ). Approximately twice as many cells of the SN, labeled retrogradely by FG or identified by TH immunoreactivity survived in the bcl-2 vector-treated animals compared with control vector-injected animals. 20 The magnitude of the protective effect of vector-mediated bcl-2 expression was similar to that reported in bcl-2 over-expressing mice exposed to 1-methyl-4-phenyl-1,2,3,G-tetrahydropyridine (MPTP) suggesting that a substantial proportion of the at-risk cells were protected by vector-mediated transgene production. Because bcl-2 is located and acts intracellularly, the neuroprotective effect would be expected to occur only in transfected cells.
It has not been established whether the degeneration of dopaminergic neurons in Parkinson's disease is correctly modeled by 6-OHDA lesioning and proceeds through apoptotic pathways. We have recently begun to explore the utility of this vector in preventing cell death in another model that is directly relevant to human disease. The peripheral nerve is relatively resistant to trauma, and peripheral axons demonstrate a remarkable ability to regenerate following injury. However, after proximal root avulsion, motor neurons in the ventral horn of spinal cord degenerate rapidly, and even prompt surgical anastamosis of the proximal stump to the distal segment fails to promote regeneration and restoration of function. It is not known whether motor neuron death following proximal root avulsion in apoptotic, but we reasoned that it if it were, the bcl-2-expressing vector might protect those cells from immediate death and allow for recovery and ultimately regeneration.
The experimental model is analogous to that employed in the 6-OHDA model. The bcl-2 expressing vector or a control vector was stereotactically injected unilaterally into the ventral horn of lumbar spinal cord. At the same time, fluorogold was injected into the sciatic nerve bilaterally in order to label motor neurons projecting into the nerve. One week later the roots were exposed and surgically avulsed. After 2 weeks survival the rats were killed. The number of surviving motor neurons determined by analysis of the fluorogold labeling demonstrated a substantial and statistically significant protective effect of vector-mediated bcl-2 expression. In contrast to the 6-OHDA lesioning experiment, bcl-2 expression did not preserve the neurotransmitter phenotype of the injured cells. Immunostaining for choline acetyltransferase (ChAT) revealed an almost complete loss of ChAT immunoreactivity in bcl-2 vector, control vector, or PBSinjected lesioned animals. The loss of cholinergic phenotype may result from the difference between the two lesions (terminal damage in 6-OHDA versus proximal damage in the spinal cord model), a difference between central and peripheral neurons, or the requirement for other factors to support the neurotransmitter expression in surviving neurons. To that end, we are now investigating whether surgical repair of the nerve allows regeneration and repair in the bcl-2 treated animals, and whether a vector expressing both the anti-apoptotic peptide and a trophic factor might be more effective than either alone.
Summary
The studies reviewed above demonstrate that it is feasible to protect neurons from a variety of insults using a genomic HSV-based vector expressing either neurotrophic factors or anti-apoptotic peptides. Transgene expression may be targeted to specific sites in the central nervous system by stereotactic inoculation, and to cells in the peripheral nervous system by retrograde axonal transport from the periphery; the transgene product may function locally, or be released to function systemically in an endocrine manner. The choice of trophic factor and antiapoptotic peptide for specific applications will need to be determined empirically, but capacity of the HSV vector makes it possible to express several transgenes simultaneously from a single vector should that prove necessary.
